Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy

Breast Journal

Volumn 18, Issue 6, 2012, Pages 569-574

  Joh, Jennifer E ^a   Esposito, Nicole N ^b   Kiluk, John V ^a   Laronga, Christine ^a   Khakpour, Nazanin ^a   Soliman, Hatem ^a   Lee, M Catherine ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

breast cancer; invasive lobular carcinoma; neo adjuvant chemotherapy; pathology; tumor response

Indexed keywords

CYCLOPHOSPHAMIDE; IXABEPILONE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; DISTANT METASTASIS; FOLLOW UP; HUMAN; MASTECTOMY; PARTIAL MASTECTOMY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

EID: 84868557355     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12006     Document Type: Article

References (35)

1. Perloff M, Lesnick GJ,. Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg 1982; 117: 879-81. (Pubitemid 12080903)
2. Schick P, Goodstein J, Moor J, Butler J, Senter KL,. Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 1983; 22: 278-82. (Pubitemid 13130121)
3. Ragaz J, Baird R, Rebbeck P, Goldie J, Coldman A, Spinelli J,. Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer 1985; 56: 719-24. (Pubitemid 15228258)
4. Sorace RA, Bagley CS, Lichter AS, et al. The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. World J Surg 1985; 9: 775-85. (Pubitemid 15241704)
5. Forrest AP, Levack PA, Chetty U, et al. A human tumour model. Lancet 1986; 2: 840-2. (Pubitemid 17178039)
6. Jacquillat CI, Weil M, Auclerc G, et al. Neoadjuvant chemotherapy in the conservative management of breast cancers: study of 143 patients. Recent Results Cancer Res 1986; 103: 113-9.
7. Ragaz J,. Emerging modalities for adjuvant therapy of breast cancer: neoadjuvant chemotherapy. NCI Monogr 1986; 1: 145-52. (Pubitemid 17200861)
8. Bonadonna G,. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992; 52: 2127-37.
9. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-93. (Pubitemid 27289876)
10. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-85. (Pubitemid 351264391)
11. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B,. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
12. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85. (Pubitemid 28363030)
13. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23: 9304-11.
14. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P,. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-8. (Pubitemid 23184384)
15. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z,. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180: 297-306.
16. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77: 621-6. (Pubitemid 28059470)
17. Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998; 4: 230-6.
18. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 12: 320-7. (Pubitemid 37322062)
19. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-22. (Pubitemid 350013847)
20. Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003; 29: 361-7. (Pubitemid 36675693)
21. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23: 41-8. (Pubitemid 41702621)
22. Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006; 17: 1228-33. (Pubitemid 44288213)
23. Katz A, Saad ED, Porter P, Pusztai L,. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 2007; 8: 55-62. (Pubitemid 44943091)
24. Farese SA, Aebi S,. Infiltrating lobular carcinoma of the breast: systemic treatment. Breast Dis 2009; 30: 45-52.
25. Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004; 40: 342-51. (Pubitemid 38121270)
26. Wenzel C, Bartsch R, Hussian D, et al. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat 2007; 104: 109-14. (Pubitemid 46976638)
27. Dillon DA, Guidi AJ, Schnitt SJ,. Chapter 28: Pathology of Invasive Breast Cancer. In:, Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast, 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2009: 374-407.
28. Wasif N, Maggard MA, Ko CY, Giuliano AE,. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 2010; 17: 1862-9.
29. Eusebi V, Magalhaes F, Azzopardi JG,. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 1992; 23: 655-62.
30. Weidner N, Semple JP,. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 1992; 23: 1167-71.
31. Buchanan CL, Flynn LW, Murray MP, et al. Is pleomorphic lobular carcinoma really a distinct clinical entity? J Surg Oncol 2008; 98: 314-7.
32. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108-16. (Pubitemid 46224019)
33. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106: 2095-103. (Pubitemid 43673229)
34. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007; 110: 244-54. (Pubitemid 47121883)
35. Olson JA Jr,., Budd GT, Carey LA, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg 2009; 208: 906-14.discussion 15-6.